[HTML][HTML] Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation-and transrepression-dependent mechanisms

EM King, JE Chivers, CF Rider, A Minnich… - PloS one, 2013 - journals.plos.org
EM King, JE Chivers, CF Rider, A Minnich, MA Giembycz, R Newton
PloS one, 2013journals.plos.org
Binding of glucocorticoid to the glucocorticoid receptor (GR/NR3C1) may repress
inflammatory gene transcription via direct, protein synthesis-independent processes
(transrepression), or by activating transcription (transactivation) of multiple anti-inflammatory/
repressive factors. Using human pulmonary A549 cells, we showed that 34 out of 39 IL-1β-
inducible mRNAs were repressed to varying degrees by the synthetic glucocorticoid,
dexamethasone. Whilst these repressive effects were GR-dependent, they did not correlate …
Binding of glucocorticoid to the glucocorticoid receptor (GR/NR3C1) may repress inflammatory gene transcription via direct, protein synthesis-independent processes (transrepression), or by activating transcription (transactivation) of multiple anti-inflammatory/repressive factors. Using human pulmonary A549 cells, we showed that 34 out of 39 IL-1β-inducible mRNAs were repressed to varying degrees by the synthetic glucocorticoid, dexamethasone. Whilst these repressive effects were GR-dependent, they did not correlate with either the magnitude of IL-1β-inducibility or the NF-κB-dependence of the inflammatory genes. This suggests that induction by IL-1β and repression by dexamethasone are independent events. Roles for transactivation were investigated using the protein synthesis inhibitor, cycloheximide. However, cycloheximide reduced the IL-1β-dependent expression of 13 mRNAs, which, along with the 5 not showing repression by dexamethasone, were not analysed further. Of the remaining 21 inflammatory mRNAs, cycloheximide significantly attenuated the dexamethasone-dependent repression of 11 mRNAs that also showed a marked time-dependence to their repression. Such effects are consistent with repression occurring via the de novo synthesis of a new product, or products, which subsequently cause repression (i.e., repression via a transactivation mechanism). Conversely, 10 mRNAs showed completely cycloheximide-independent, and time-independent, repression by dexamethasone. This is consistent with direct GR transrepression. Importantly, the inflammatory mRNAs showing attenuated repression by dexamethasone in the presence of cycloheximide also showed a significantly greater extent of repression and a higher potency to dexamethasone compared to those mRNAs showing cycloheximide-independent repression. This suggests that the repression of inflammatory mRNAs by GR transactivation-dependent mechanisms accounts for the greatest levels of repression and the most potent repression by dexamethasone. In conclusion, our data indicate roles for both transrepression and transactivation in the glucocorticoid-dependent repression of inflammatory gene expression. However, transactivation appears to account for the more potent and efficacious mechanism of repression by glucocorticoids on these IL-1β-induced genes.
PLOS